Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients
暂无分享,去创建一个
H Rollag | A Humar | A. Åsberg | H. Rollag | M. Pescovitz | A. Hartmann | A. Jardine | A. Humar | A. Humar | M. Tuncer | M Tuncer | M D Pescovitz | I L Noronha | A Asberg | A G Jardine | H Mouas | D Sgarabotto | A Hartmann | I. Noronha | D. Sgarabotto | H. Mouas | A. Åsberg
[1] R. Willemze,et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients , 2006, Bone Marrow Transplantation.
[2] B. Alexander,et al. Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] J. Itskovitz‐Eldor,et al. Human embryonic stem cells: A potential source for cellular therapy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] D. Dunn,et al. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. , 1999, Transplantation.
[5] H. Rollag,et al. Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[6] A. Burroughs,et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. , 2005, Journal of Infectious Diseases.
[7] M. Degli-Esposti,et al. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection , 2007, Immunology and cell biology.
[8] V. Emery,et al. Management of CMV infection and disease in transplant patients. 27-29 February 2004. , 2004, Herpes : the journal of the IHMF.
[9] H. Rollag,et al. A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1 , 2000, Transplantation.
[10] M. van der Giessen,et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. , 1993, Transplantation.
[11] Deepali Kumar,et al. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. , 2003, The Journal of infectious diseases.
[12] J. Preiksaitis,et al. Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] D. Lilleri,et al. Monitoring of Human Cytomegalovirus‐Specific CD4+ and CD8+ T‐Cell Immunity in Patients Receiving Solid Organ Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] Guy Boivin,et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. , 2002, The Journal of infectious diseases.
[15] A. Caliendo,et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. , 2000, Journal of clinical microbiology.
[16] S. Walmsley,et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. , 2002, Journal of acquired immune deficiency syndromes.
[17] A. Humar,et al. American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] Daniel F. Martin,et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. , 2002, The New England journal of medicine.
[19] J. Gómez-Moreno,et al. Infection in organ-transplant recipients. , 1998, The New England journal of medicine.
[20] T. F. Smith,et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. , 2000, The Journal of infectious diseases.
[21] J. Rabkin,et al. Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients , 2000, Antimicrobial Agents and Chemotherapy.
[22] Risto S. Cvetković,et al. Valganciclovir , 2012, Drugs.
[23] Barbara Alexander,et al. Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients , 2005, Clinical pharmacokinetics.
[24] Thomas F. Smith,et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. , 2003, The Journal of infectious diseases.
[25] D. Jung,et al. Single‐Dose Pharmacokinetics of Valganciclovir in HIV‐ and CMV‐Seropositive Subjects , 1999, Journal of clinical pharmacology.
[26] M. Pescovitz. Valganciclovir: what is the status in solid organ transplantation? , 2006 .